The Fred Hutch Bone Marrow Transplant Program at Seattle Cancer Care Alliance (SCCA) has been recognized by the Center for International Blood and Marrow Transplant Research® (CIBMTR) for outperforming its expected one-year survival rates for allogeneic transplant patients – those who receive donated adult blood-forming stem cells. SCCA’s program is one of only five programs to exceed expectations for at least six years in a row.
Comparing transplant centers
To arrive at its findings, CIBMTR independently examined the survival rates of 24,141 allogeneic transplant patients treated at U.S. centers in the National Marrow Donor Program network. The reporting period for the 2018 report covered Jan. 1, 2014 to Dec. 31, 2016. During this period, 788 allogeneic transplants were performed at SCCA and met the criteria for the study.
The report, published annually, is required by federal law and is designed to provide potential stem cell transplant recipients, their families and the public with comparative survival rates among transplant centers.
Research improves your care
“We are extremely proud that patients receiving allogeneic bone marrow transplants at SCCA can expect survival rates that are consistently better than the expected one-year survival rates,” said Dr. Marco Mielcarek, medical director for the Adult Bone Marrow Transplant Program at SCCA and associate member of the Clinical Research Division at Fred Hutch.
“Outcomes are attributable to many factors, but our dedicated team and their decades of transplant experience and groundbreaking research are important contributors to sustaining exceptional outcomes. Our research has yielded consistent improvements in efficacy and safety of stem cell transplantation. Our team is committed to continued improvements in outcomes for all our patients.”